CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oncodesign Precision Medicine Opm SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oncodesign Precision Medicine Opm SA
18 Rue Jean Mazen
DIJON, 21000  France Ticker: ALOPMALOPM
Business Summary
Oncodesign Precision Medicine Opm SA is a France-based biopharmaceutical company specialized in precision medicine. It aims at providing effective diagnostic and therapeutic solutions for resistant and metastatic cancers. The Company’s technologies from Oncodesign, are OncoSNIPER for the selection of therapeutic targets using artificial intelligence; Nanocyclix for the design and selection of macrocyclic small molecule kinase inhibitors and Theranostics for the design and selection of radiolabeled biological molecules for systemic radiotherapy. It focuses on the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

General Information
Number of Employees: 21 (As of 6/30/2023)
Outstanding Shares: 16,566,653 (As of 6/30/2023)
Stock Exchange: EPA


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024